Reldesemtiv clinical trials
Also written CK-2127107.
How each study uses reldesemtiv is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Cytokinetics (4) · Astellas Pharma Global Development, Inc. (2)
Studies
Open first, then newest update. How each study uses reldesemtiv is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)TerminatedPhase 3CytokineticsNCT04944784Written as ReldesemtivHow we know
- A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Astellas Pharma Global Development, Inc.NCT02662582Written as ReldesemtivHow we know
- A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in MobilityTerminatedPhase 1Astellas Pharma Global Development, Inc.NCT03065959Written as reldesemtivHow we know
- A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)TerminatedPhase 3CytokineticsNCT05442775Written as ReldesemtivHow we know
- A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2CytokineticsNCT03160898Written as ReldesemtivHow we know
- A Study of CK-2127107 in Patients With Spinal Muscular AtrophyCompletedPhase 2CytokineticsNCT02644668Written as Reldesemtiv 150 mgHow we know
Codes
What other systems call reldesemtiv · ClinicalTrials.gg INT001860
- MeSH (NLM) C000722562reldesemtivOne source NLM
- UNII (FDA) 4S0HBYW6QERELDESEMTIVConfirmed FDA, NLM
- NCI Thesaurus C166781ReldesemtivOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722562 | reldesemtiv | One source NLM |
| UNII (FDA) | 4S0HBYW6QE | RELDESEMTIV | Confirmed FDA, NLM |
| NCI Thesaurus | C166781 | Reldesemtiv | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.